Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

(2022) Alexandra C. Walls et al.   CELL

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea

(2022) Min-Kyung Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021

(2022) Linda Houhamdi et al.   JOURNAL OF MEDICAL VIROLOGY

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

(2022) Nicole Wolter et al.   LANCET

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

(2022) Huiping Shuai et al.   NATURE

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

(2022) Kenrie P. Y. Hui et al.   NATURE

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

(2022) Thiago Cerqueira-Silva et al.   NATURE MEDICINE

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

(2022) Yu Gao et al.   NATURE MEDICINE

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

(2022) Samuel M. S. Cheng et al.   NATURE MEDICINE

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

(2022) Eddy Pérez-Then et al.   NATURE MEDICINE

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses

(2022) Runhong Zhou et al.   Clinical and Translational Medicine

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

(2022) Rishi R. Goel et al.   CELL

Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak

(2022) Vincent Chi-Chung Cheng et al.   CLINICAL INFECTIOUS DISEASES

The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants

(2022) Marios Koutsakos et al.   IMMUNITY

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study

(2022) Cristina Menni et al.   LANCET

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

(2022) Sho Iketani et al.   NATURE

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

(2022) Roanne Keeton et al.   NATURE

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

(2022) Frauke Muecksch et al.   NATURE

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

(2022) Laurence Chu et al.   NATURE MEDICINE

Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers

(2022) Sarang K. Yoon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants

(2022) Jingyou Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong

(2022) Qiaoli Peng et al.   EBioMedicine

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

(2022) Jasmin Quandt et al.   Science Immunology

Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection

(2022) Chengzi I. Kaku et al.   Science Immunology

Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?

(2022) Menno C. van Zelm   Science Immunology

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron

(2022) Nungruthai Suntronwong et al.   Vaccines

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

(2022) Aekkachai Tuekprakhon et al.   CELL

Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study

(2022) Martina E McMenamin et al.   LANCET INFECTIOUS DISEASES

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

(2022) Qian Wang et al.   NATURE

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants

(2022) João Malato et al.   NEW ENGLAND JOURNAL OF MEDICINE

Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract

(2022) Kenrie P.Y. Hui et al.   EBioMedicine

Adaptive immunity to SARS-CoV-2 and COVID-19

(2021) Alessandro Sette et al.   CELL

Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies

(2021) Dongyan Zhou et al.   Cell Host & Microbe

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

(2021) Laith J. Abu-Raddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model

(2021) Bart L Haagmans et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves

(2021) Caroline Maslo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon

(2021) Rima Moghnieh et al.   VACCINE

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

(2020) Runhong Zhou et al.   IMMUNITY

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

(2020) Nina Le Bert et al.   NATURE

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

(2020) Jennifer A. Juno et al.   NATURE MEDICINE

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE